Business Context and Reporting Period
This Form 8-K is a current report filed by Imprimis Pharmaceuticals, Inc. (noted as Harrow, Inc. in metadata) on November 12, 2015. The filing serves to announce the company's financial results for the third quarter ended September 30, 2015, which are detailed in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided filing text acts as a cover document and does not contain specific numerical data. Consequently, values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this text. The filing explicitly states that the detailed financial results are contained within the attached press release (Exhibit 99.1), which is not included in the input source.
Material Changes
The filing text does not provide specific details regarding material changes versus the prior comparable period. It only confirms the issuance of the Q3 2015 results announcement.
Guidance, Outlook, and Risks
The filing includes standard legal disclaimers regarding the information furnished under Item 2.02:
- The information is not deemed "filed" under Section 18 of the Exchange Act.
- The company does not assume any obligation to update the information in the future.
- The filing does not constitute an admission that the information is required under Regulation FD.
No specific guidance, outlook, or risk factors are detailed in the text of this 8-K form itself.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing Exhibit 99.1 (the press release dated November 12, 2015), as they are absent from this summary text.
- Confirm the company's current name status, as the metadata lists "Harrow, Inc." while the filing text identifies the registrant as "Imprimis Pharmaceuticals, Inc."
- Review the full press release for any forward-looking statements or operational updates not captured in this procedural filing.